R. Loyon

Type de document

Co-auteur

S. Trabanelli

C. Jandus

A. Gomez-Cadena

T. Wyss

G. Vanoni

P. Romero

P.C. Ho

C. Borg

G. Verdeil

A. Tozzo

P. Tentorio

M. Suffiotti

A. Steinle

L. Spehner

A. Schulz

V. Salvestrini

S. Salvatore

B. Salomé

D.F. Ruan

M. Rossi

C. Riether

A. Ochsenbein

K. Michaud

L. Michalik

D. Merkler

D. Mavilio

E. Marcenaro

M. Kroemer

M. Kreutzfeldt

P. Krebs

M. Kopf

M.B. Khelil

P. Jandus

E.M. Jacobsen

A. Ianaro

A Horowitz

M. Hoenig

D. Gfeller

G. Ercolano

N. Dumauthioz

M.G. Della Porta

A. Curti

C. Conrad

E. Bruni

K. Bouiller

Date

Source

Serveur académique Lausannois (3)

Mot-clé

Human beings (3) immunité (2) Population (2) Patients (2) Immunity (2) Functions (2) Cells (2) Population (2) Patients (2) spectacle (1) marqueur (1) gène (1) allergie (1) famille (1) effet (1) cytotoxicité (1) pièce d'exposition (1) cancer (1) taux (1) survie (1) Diagnosis (1) Deletion (1) Blockades (1) Cancer (1) Diseases (1) Phenotype (1) Acute myeloid leukemia (1) Protection (1) Tumors--Growth (1) Tissues (1)

Documents écrit par R. Loyon (3) | parle de R. Loyon (0)

PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.

G. Ercolano et al. (5 mai 2021)

Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment.

A. Gomez-Cadena et al.

CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.

B. Salomé et al. (26 nov. 2019)